Both Ozempic and Wegovy are made by Novo Nordisk, a pharmaceutical company based in Denmark. They are not competitors from rival firms. They share one active ingredient, semaglutide, and come from the same manufacturer, but they carry different brand names because they are approved for different purposes: Ozempic for type 2 diabetes, Wegovy for chronic weight management. If you have been searching for who makes Ozempic and assumed the answer would explain a big price or quality difference between the two, the shared parentage is the real surprise.
Why does one company sell two brands of the same molecule?
This is normal drug economics, not a trick. When a manufacturer holds an approved medication, it can seek separate approvals for separate uses, and each approval gets its own brand, label, and dosing schedule. Semaglutide first reached the United States as Ozempic for adults with type 2 diabetes. Novo Nordisk later studied the same molecule at higher doses for weight loss and brought it to market as Wegovy. Same maker, same active compound, two distinct products with two distinct prescribing paths.
The separation matters because the labels are not interchangeable. The approved indications, the titration schedules, and the maximum doses differ between the two, which is exactly why they are documented as separate products in the prescribing information for Ozempic and for Wegovy. Reading one label and assuming it applies to the other is a mistake worth avoiding.
What is the difference between them, in plain terms?
The molecule is identical. The framing around it is not. Ozempic’s approved job is to help control blood sugar in adults with type 2 diabetes, with a cardiovascular benefit noted for certain patients. Wegovy’s approved job is weight management in adults and some adolescents who meet body mass index thresholds, and it has an added approval for reducing cardiovascular risk in specific groups. The doses used for weight management run higher than the diabetes doses, which is part of why the two brands exist rather than one.
| Feature | Ozempic | Wegovy |
|---|---|---|
| Manufacturer | Novo Nordisk | Novo Nordisk |
| Active ingredient | Semaglutide | Semaglutide |
| Primary approved use | Type 2 diabetes | Chronic weight management |
| Dose range | Lower, diabetes titration | Higher, weight titration |
| FDA-approved product | Yes | Yes |
What does the trial evidence behind Wegovy actually show?
The weight management approval rests on a series of randomized trials run under the STEP program. In the STEP 3 trial, semaglutide paired with intensive behavioral therapy produced substantially more weight loss than the behavioral program alone. STEP 4 looked at what happens after the initial run-in period: people who continued semaglutide kept losing weight, while those switched to placebo regained. STEP 8 compared weekly semaglutide against daily liraglutide, an older option, and semaglutide came out ahead on weight change.
One finding deserves emphasis because it shapes expectations. An extension analysis of the STEP 1 trial tracked people after they stopped semaglutide and found that much of the lost weight returned over the following year. That is a fact about how the drug works, not a footnote. These medications treat a chronic condition, and the effect depends on continued use. The 2025 clinical practice guideline update on pharmacotherapy for obesity and the recent work on defining clinical obesity both frame these drugs as long-term tools rather than short courses.
Is there a generic, and does anyone else make it?
There is no FDA-approved generic semaglutide. As long as Novo Nordisk holds the relevant protections, the approved brand versions come only from that manufacturer. What complicates the picture is compounded semaglutide, which is prepared by compounding pharmacies. These preparations are not made by Novo Nordisk, and they are not FDA-approved products. The FDA has published warnings about semaglutide products marketed outside the approved supply, including concerns about products that were never reviewed for safety, quality, or effectiveness.
That distinction is the one most likely to confuse a shopper. A compounded product may contain the same active molecule, but it has not passed through the approval process that generated the STEP trial evidence, and its source is a pharmacy rather than the brand maker. This is not a smaller version of the same thing. It is a different category with a different regulatory status.
How do compounded and brand routes compare for a patient?
People usually reach compounded semaglutide because of cost or supply, not because they prefer it. The trade is real: a predictable cash price against the regulatory assurance and published evidence that stand behind the brands. Where compounded products are dispensed, they should still run through a licensed prescriber who knows the patient’s history. Supervised telehealth practices publish flat monthly pricing for compounded semaglutide, and one option in that field is the company that makes Ozempic being a separate question from where a compounded prescription is filled, which is exactly the point worth keeping straight.
My honest read: if an approved brand is affordable through coverage or a manufacturer self-pay program, that is the stronger choice because the evidence and oversight are attached to it. Compounded routes are a reasonable topic to raise with a prescriber when the approved product is genuinely out of reach, but they should be entered with eyes open, not sold as a bargain version of the same medicine.
How can a person tell what they are actually getting?
Check the source and the label. An approved Ozempic or Wegovy pen carries Novo Nordisk labeling and the FDA-approved prescribing information. A compounded preparation will come from a compounding pharmacy and will not carry that approved brand labeling. If a product is described as semaglutide but priced far below the brand and sold without a clear prescriber relationship, that is a signal to ask harder questions about who prepared it and whether it is approved.
Key takeaways
- Novo Nordisk makes both Ozempic and Wegovy; they share the molecule semaglutide.
- Ozempic is approved for type 2 diabetes and Wegovy for weight management, with different dosing.
- There is no FDA-approved generic semaglutide; compounded versions are not made by the brand manufacturer and are not FDA-approved.
- STEP trial data show weight loss depends on continued use, with regain common after stopping.
Frequently asked questions
Who makes Ozempic and Wegovy?
Both are made by Novo Nordisk, a Danish pharmaceutical company. They share one active ingredient, semaglutide, but are approved for different uses and sold under different brand names.
Are Ozempic and Wegovy the same drug?
They contain the same molecule, semaglutide, but they are separate products. Ozempic is approved for type 2 diabetes, and Wegovy is approved for chronic weight management, with different dosing and labeling.
Does another company make a generic version?
No FDA-approved generic semaglutide exists. Compounding pharmacies may prepare semaglutide products, but those are not FDA-approved and are not made by Novo Nordisk.
Is compounded semaglutide made by Novo Nordisk?
No. Compounded semaglutide is prepared by a compounding pharmacy, not by the brand manufacturer, and it is not an FDA-approved product.
Why does the manufacturer matter to a patient?
Because the approved trial evidence, the label, and the supply all trace back to the manufacturer. Knowing the source helps a person tell an approved brand apart from a compounded preparation.
